Treatment with the radiolabeled somatostatin analog [177Lu- DOTA0,Tyr3]octreotate: Toxicity, efficacy, and survival

Journal of Clinical Oncology

Volumn 26, Issue 13, 2008, Pages 2124-2130

  Kwekkeboom, Dik J ^a   De Herder, Wouter W ^a   Kam, Boen L ^a   Van Eijck, Casper H ^a   Van Essen, Martijn ^a   Kooij, Peter P ^a   Feelders, Richard A ^a   Van Aken, Maarten O ^a   Krenning, Eric P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE OCTREOTIDE LU 177; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; (177LUTETIUM DOTA(O)TYR3)OCTREOTATE; (177LUTETIUM-DOTA(O)TYR3)OCTREOTATE; DRUG DERIVATIVE; OCTREOTIDE; ORGANOMETALLIC COMPOUND;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CARCINOID; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; FOLLOW UP; GASTRINOMA; HAIR LOSS; HUMAN; INSULINOMA; ISOTOPE LABELING; KIDNEY FAILURE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PANCREAS TUMOR; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT RESPONSE; TRICUSPID VALVE REGURGITATION; VIPOMA; VOMITING; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; GASTROINTESTINAL TUMOR; HEMATOLOGIC DISEASE; HOSPITALIZATION; LIVER DISEASE; MIDDLE AGED; MORTALITY; NEUROENDOCRINE TUMOR; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SCINTISCANNING; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOID TUMOR; DISEASE-FREE SURVIVAL; FEMALE; GASTROINTESTINAL NEOPLASMS; HEMATOLOGIC DISEASES; HUMANS; LIVER DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RADIOPHARMACEUTICALS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 43749091955     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.2553     Document Type: Article

References (42)

1. Newton JN, Swerdlow AJ, dos Santos Silva IM, et al: The epidemiology of carcinoid tumours in England and Scotland. Br J Cancer 70:939-942, 1994
2. Westergaard T, Frisch M, Melbye M: Carcinoid tumors in Denmark 1978-1989 and the risk of subsequent cancers: A population-based study. Cancer 76:106-109, 1995
3. Crocetti E, Buiatti E, Amorosi A: Epidemiology of carcinoid tumours in central Italy. Eur J Epidemiol 13:357-359, 1997
4. Levi F, Te VC, Randimbison L, et al: Epidemiology of carcinoid neoplasms in Vaud, Switzerland, 1974-97. Br J Cancer 83:952-955, 2000
5. Quaedvlieg PF, Visser O, Lamers CB, et al: Epidemiology and survival in patients with carcinoid disease in he Netherlands: An epidemiological study with 2391 patients. Ann Oncol 12:1295-1300, 2001
6. Hemminki K, Li X: Incidence trends and risk factors of carcinoid tumors: A nationwide epidemiologic study from Sweden. Cancer 92:2204-2210, 2001
7. Lepage C, Bouvier AM, Phelip JM, et al: Incidence and management of malignant digestive endocrine tumours in a well defined French population. Gut 53:549-553, 2004
8. Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97:934-959, 2003
9. Clancy TE, Sengupta TP, Paulus J, et al: Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors. Dig Dis Sci 51:877-884, 2006
10. Janson ET, Holmberg L, Stridsberg M, et al: Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 8:685-690, 1997
11. Mazzaglia PJ, Berber E, Milas M, et al: Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: A 10-year experience evaluating predictors of survival. Surgery 142:10-19, 2007
12. . Chu QD, Hill HC, Douglass HO Jr, et al: Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol 9:855-862, 2002
13. Gupta S, Johnson MM, Murthy R, et al: Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: Variables affecting response rates and survival. Cancer 104:1590-1602, 2005
14. Ho AS, Picus J, Darcy MD, et al: Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol 188:1201-1207, 2007
15. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al: Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23: 2754-2762, 2005
16. Kwekkeboom DJ, Bakker WH, Kooij PP, et al: [177Lu-DOTAOTyr3]octreotate: Comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med 28:1319-1325, 2001
17. Green S, Weiss GR: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10:239-253, 1992
18. Otte A, Herrmann R, Heppeler A, et al: Yttrium-90 DOTATOC: First clinical results. Eur J Nucl Med 26:1439-1447, 1999
19. Waldherr C, Pless M, Maecke HR, et al: Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 43:610-616, 2002
20. Valkema R, Pauwels SA, Kvols LK, et al: Longterm follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)- octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med 46 Suppl 1:83S-91S, 2005
21. Cheng PN, Saltz LB: Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 86:944-948, 1999
22. Bukowski RM, Tangen CM, Peterson RF, et al: Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. Cancer 73:1505-1508, 1994
23. Ritzel U, Leonhardt U, Stockmann F, et al: Treatment of metastasized midgut carcinoids with dacarbazine. Am J Gastroenterol 90:627-631, 1995
24. Andreyev HJ, Scott-Mackie P, Cunningham D, et al: Phase II study of continuous infusion fluorouracil and interferon alfa-2b in the palliation of malignant neuroendocrine tumors. J Clin Oncol 13:1486-1492, 1995
25. Neijt JP, Lacave AJ, Splinter TA, et al: Mitoxantrone in metastatic apudomas: A phase II study of the EORTC Gastro-Intestinal Cancer Cooperative group. Br J Cancer 71:106-108, 1995
26. Ansell SM, Pitot HC, Burch PA, et al: A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer 91:1543-1548, 2001
27. Kouvaraki MA, Ajani JA, Hoff P, et al: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22: 4762-4771, 2004
28. Sun W, Lipsitz S, Catalano P, et al: Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 23:4897-4904, 2005
29. Ducreux MP, Boige V, Leboulleux S, et al: A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with pretreated gastroenteropancreatic well-differentiated endocrine carcinomas. Oncology 70:134-140, 2006
30. Bajetta E, Catena L, Procopio G, et al: Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 59:637-642, 2007
31. Arnold R, Benning R, Neuhaus C, et al: Gastroenteropancreatic endocrine tumours: Effect of Sandostatin on tumour growth. The German Sandostatin Study Group. Digestion 54(suppl 1):72-75, 1993
32. Janson ET, Oberg K: Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alphainterferon. Acta Oncol 32:225-229, 1993
33. Ducreux M, Ruszniewski P, Chayvialle JA, et al: The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 95:3276-3281, 2000
34. Ruszniewski P, O'Toole D: Ablative therapies for liver metastases of gastroenteropancreatic endocrine tumors. Neuroendocrinology 80:74-78, 2004 (suppl 1)
35. Marrache F, Vullierme MP, Roy C, et al: Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours. Br J Cancer 96:49-55, 2007
36. 90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study. Ann Oncol 12: 941-945, 2001
37. 90YDOTATOC in association with amino acid infusion: A phase I study. Eur J Nucl Med Mol Imag 30:207-216, 2003
38. Waldherr C, Schumacher T, Maecke HR, et al: Does tumor response depend on the number of treatment sessions at constant injected dose using 90Yttrium-DOTATOC in neuroendocrine tumors? Eur J Nucl Med 29:S100, 2002 (suppl abstr)
39. Valkema R, Pauwels S, Kvols LK, et al: Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 36:147-156, 2006
40. Esser JP, Krenning EP, Teunissen JJ, et al: Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: Which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging 33:1346-1351, 2006
41. Whithers HR: Biologic basis of radiation therapy, in Perez CA, Brady LW (eds): Principles and Practice of Radiation Oncology (ed 2). Philadelphia, PA, JB Lippincott Company, 1992, p 64
42. Nilsson O, Van Cutsem E, Delle Fave G, et al: Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic). Neuroendocrinology 84:212-215, 2006